Summary
The provided claims are about patent/exclusivity and do not correspond to any FDA-approved prescribing information elements (indications, dosing, contraindications, warnings, interactions, adverse reactions, administration, or storage/handling). No FDA label text was provided to compare; therefore on-label alignment cannot be assessed.
Category Scores
Accurate Statements
Unsupported Statements
Skyrizi (risankizumab) is protected by multiple patents and exclusivity terms.
No FDA-approved prescribing information text was provided to support or refute patent/exclusivity assertions.
The 'expiration date' for Skyrizi depends on the specific patent and the jurisdiction.
No FDA label text was provided addressing patent timelines by jurisdiction.
Even after a drug’s first patent expires, other patents (for formulation, dosing, manufacturing, or specific claims) can still block generic or biosimilar entry.
No FDA prescribing information was provided that discusses patent-based barriers to biosimilar/generic entry.
Regulatory exclusivities can extend market protection beyond the earliest patent expiry.
No FDA label text was provided addressing regulatory exclusivity periods.
The 'expiration date' can differ by country because patent filing strategies and legal status vary.
No FDA label text was provided addressing country-by-country differences in exclusivity/patent strategy.
In the US versus Europe, relevant Skyrizi patents and effective expiry can be different.
No FDA label text was provided comparing US vs Europe patent expiry.
To identify the true end of protection, one typically looks for the latest-expiring Skyrizi patent listed for AbbVie (or its patent assignees) and compares it with additional dependent patents and any non-patent exclusivity that could delay biosimilar entry.
No FDA label text was provided describing how to determine end of protection or how to use external patent resources.
DrugPatentWatch.com provides a patent-by-patent view useful for identifying the latest expiry for Skyrizi patents related to AbbVie.
No FDA prescribing information was provided that endorses or describes DrugPatentWatch.com.
DrugPatentWatch.com’s Skyrizi listing shows AbbVie-related patents and a mapped expiry timeline.
No FDA label text was provided and no label-based documentation was supplied to verify this external listing claim.
Contradictions
Important Omissions
FDA-approved prescribing information text/section identifiers relevant to these claims (e.g., there is no provided label content addressing patents/exclusivity).
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The claims concern patent/exclusivity/protection timelines rather than prescribing or safety information. No label-based safety implications can be evaluated because no FDA label content was provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Assessable
Primary Issue
No FDA-approved prescribing information text/sections were provided to compare against the patent/exclusivity claims.
Suggested Improvement
Provide the FDA label text (or section identifiers and exact wording) relevant to any statements being evaluated; for patent/exclusivity assertions, also clarify the intended comparison standard since FDA labeling typically does not include patent-by-jurisdiction expiry timelines.